biostudies-literatureUnknown58(10)Manning JDihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg pAntimicrobial agents and chemotherapy6056-67https://www.ebi.ac.uk/biostudies/studies/S-EPMC4187937biostudies-literatureRandomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.PMC4187937Sriwichai SLanteri CChour CMVanachayangkul PTang DSe YProm SSo MSiripokasupkul RSea DSaunders DSoh ETeja-Isavadharm PManning JKaewkungwal JSomethy SSpring MCantilena LChann SLon CMitprasat MKuntawunginn WPhann STAuayporn MBuathong NHaigney MTimmermans AfalseRandomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg p2014-01-01T00:00:00Z2014 Oct2026-04-29T19:37:53.872Z2019-03-26T23:50:36ZS-EPMC41879372509270210.1128/aac.02667-1410.1128/AAC.02667-14